TMCnet News
NSCLC Therapeutics in Asia-Pacific Markets is Expected to Grow CAGR 6.3% By 2019: ResearchMoz.us(PR Web Via Acquire Media NewsEdge) Albany, NY (PRWEB) March 09, 2014 NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019. View full report with complete TOC at http://www.researchmoz.us/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool-report.html. The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim’s Gilotrif, Eli Lilly’s necitumumab, Bristol-Myers Squibb’s Yervoy (ipilimumab) and nivolumab, Pfizer’s dacomitinib and Novartis’s LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries. Browse all reports in therapeutic area at http://www.researchmoz.us/therapeutic-area-market-reports-37.html Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in Australia, China, India and Japan. It includes: A brief introduction to NSCLC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms In-depth analysis of currently marketed drugs for NSCLC, including analysis of their safety, efficacy, treatment patterns and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy A comprehensive review of the pipeline for NSCLC, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period, analyzed on the basis of phase distribution, molecule type, program type, mechanisms of action and molecular target Additional in-depth analysis of pipeline drug clinical trials, by Phase, trial size, trial duration and program failure rate, for each molecule type Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets Discussion of the drivers of and barriers to market growth In-depth analysis of all licensing and co-development deals that have occurred in the NSCLC market since 2006 Browse other published reports by GBI Research at http://www.researchmoz.us/publisher/gbi-research-2.html. Reasons to Buy The report will enhance your decision-making capability by allowing you to: Understand the NSCLC pipeline and the factors that indicate that it is becoming more innovative Observe detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be Follow the trends in NSCLC clinical trial size and duration in relation to industry averages Assess the potential risk of future developmental programs for NSCLC therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates Observe the potential growth patterns expected for the NSCLC market over the forecast period Identify which countries are expected to contribute the most to this growth and devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the NSCLC market Accelerate and strengthen your market position by identifying key companies for strategic partnerships Related Reports - Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion. View full report with complete TOC at http://www.researchmoz.us/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-report.html. Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. View full report with complete TOC at http://www.researchmoz.us/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-description-report.html. About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Browse Blog - http://pramoddige91.wordpress.com/. Read the full story at http://www.prweb.com/releases/2014/03/prweb11649144.htm (c) 2014 PRWEB.COM Newswire |